can help diagnose or follow up on the progress of a variety of diseases, including Huntington’s Disease, olivopontocerebellar atrophy, epilepsy, schizophrenia, as well as hepatitis, cirrhosis, cholangitis, Gilbert’s diseases, muscular dystrophy, leukemia, kidney inflammation, cardiac infarction, or the presence of a tumor. Thus, tissue AST activity may become a novel marker of brain disorders which has been inaccessible using current clinical technologies.

Applications and Market: Diagnosis and monitoring disease status in a variety of diseases, including Huntington’s Disease, olivopontocerebellar atrophy, epilepsy, schizophrenia, as well as hepatitis, cirrhosis, cholangitis, Gilbert’s diseases, muscular dystrophy, leukemia, kidney inflammation, cardiac infarction, or the presence of a tumor. The diagnostic market is a multi-billion dollar market, with a need for more efficient non-invasive techniques, markers and new methods of diagnosis.


Inventors: Dr. Jun Shen (NIMH).


Licensing Status: Available for exclusive or non-exclusive licensing.

Licensing Contact: Chekesha Clingman, Ph.D.; 301/435–5018; clingman@mail.nih.gov.


Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 06–7436 Filed 9–5–06; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel; NIMH Eating Disorders Grant Application Review.

Date: September 29, 2006.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Bettina D. Osborn, Ph.D., Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6154, MSC 9609, Rockville, MD 20852–9609, 301–435–1178, acunab@mail.nih.gov.

Name of Committee: National Institute of Mental Health Special Emphasis Panel; Mental Health Centers for Intervention Development and Applied Research (CIDAR).

Date: October 12–13, 2006.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Park Hotel, 8400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: A. Roger Little, Ph.D., Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6157, MSC 9609, Rockville, MD 20852–9609, 301–402–5844, alittle@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)


Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 06–7434 Filed 9–5–06; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institutes of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting

Notice is hereby given of changes in the meeting of the National Institutes of Diabetes and Digestive and Kidney Diseases Advisory Council, September 20, 2006, 8:30 a.m. to September 21, 2006, 12 p.m., National Institutes of Health, Building 31, 31 Center Drive, Bethesda, MD 20892, which was published in the Federal Register on August 18, 2006, 71 FR 47820–47821.

Name of Committee: National Institutes of Diabetes and Digestive and Kidney Diseases Advisory Council.

Date: September 20–21, 2006.
Open: September 20, 2006, 8:30 a.m. to 12 p.m.
Agenda: To present the Director’s Report and other scientific presentations.
Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.

Open: September 20, 2006, 4 p.m. to 5 p.m.
Agenda: Report from the NIH Director.
Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.
Closed: September 21, 2006, 9:45 a.m. to 10:15 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.

Open: September 21, 2006, 10:15 a.m. to 12 p.m.
Agenda: Continuation of the Director’s Report and other scientific presentations.
Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.

Contact Person: Brent B. Stanfield, Ph.D., Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd.,